News and Trends 3 Dec 2014
New Technologies Against Allergies are on the Wave
Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]
